These ideas are primarily based on hypotheses and the understanding of mechanisms and dose-response from clinical trials, rather than on direct microdosing data
If youve missed two consecutive doses or more, most clinicians recommend restarting at a lower dose
Private market access of GLP-1 RA was 6.6 DDD/1000/day, estimated to cover 0.7% of the Australian population at a standard daily maintenance dose
She's straightforward, knows her stuff, and has a way of making treatments feel easy. I was brought to the back where the nurse Angelika answered all my questions in great detail and made me feel comfortable asking any questions that I had without making me feel bad
Our findings provide supportive evidence for preferential consideration of GLP-1RAs over DPP-4i in this high-risk population
Retatrutide remains under regulatory review in early-phase trials, with ongoing studies evaluating safety, efficacy, and long-term therapeutic potential